Obsidian Therapeutics, Inc.

OBX · Nasdaq · United States

Share price · OBX

$12.21-7.74 (-38.80%) 3M

close as of 2026-11-18 · 24h delayed · vol 681K (1.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when OBX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+44.4%
  2. 4 Nov 2026-16.9%

Share of unusual movement by asset

For each asset, the share of OBX's own-move activity since 30 Jul 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
OBX-115
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—17%
Other company news (earnings, financing, releases naming no asset)—52%
Sessions with no dated event—31%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 1/2
IL-15 receptor signalingCell therapy
Non-Small Cell Lung CancerMelanoma

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
June 2029 (1)
OBX-115Phase 1/2Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer …
Est. primary completion 2029-06-30 · NCT06060613 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$28M$68M+ $148M short-term inv.$51M-$37M operating cash flowreport ↗
View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2——$0+ $16M short-term inv.—$0 operating cash flowreport ↗
2025-Q3$0$25M$37M$28M-$21M operating cash flowreport ↗
2025-Q2$0$23M—$27Mreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$86M$40M+ $40M short-term inv.$25M-$90M operating cash flowreport ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$73M$50M+ $119M short-term inv.$21M-$75M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-10Reisenauer Mark L · directorAward / grant (derivative)75,364——Form 4
2026-08-03Jagasia Madan · director, Chief Executive OfficerAward / grant (derivative)678,477——Form 4
2026-08-03Hari Parameswaran · Chief Medical OfficerAward / grant (derivative)331,173——Form 4
2026-08-03Feder Julie B · Chief Financial OfficerAward / grant (derivative)164,790——Form 4
2026-08-03Fardis Maria · directorAward / grant (derivative)37,653——Form 4
2026-08-03Hagen Heidi · directorAward / grant (derivative)37,653——Form 4
2026-08-03Barrett Peter · directorAward / grant (derivative)37,653——Form 4
2026-08-03Jagasia Madan · director, Chief Executive OfficerAward / grant (derivative)37,653——Form 4